COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- World's largest superconducting magnet for fusion reactor unveiled in Hefei
- 'Enjoyable Silver Age' to rejuvenate aging population
- Annual sci-tech conference to host 118 themed forums in July
- Nigerian political parties committed to good governance and anti-corruption
- Shanghai opens new talent home to support cultural creators
- BRI paves the path toward a shared future, enabling people of all countries to pursue a life of dignity
